Compare Stocks → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:EYEGOTCMKTS:MATNNASDAQ:NVUS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEYEGAB Corporate Bond ETF$35.09-0.2%$1.90$1.44▼$8.18$24.57M0.13935,975 shs4 shsMATNMateon Therapeutics$0.04$0.04$0.13▼$0.38$3.56M1.33338,444 shs5,064 shsNVUSNovus Therapeutics$2.44+8.0%$13.23$4.50▼$27.32$3.50M2.0778,851 shs394,113 shs7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEYEGAB Corporate Bond ETF+0.15%+1.38%-0.05%-1.00%+1,703.88%MATNMateon Therapeutics-4.57%-10.48%-6.00%-5.41%-16.44%NVUSNovus Therapeutics-7.38%-5.44%+31.40%+24.86%-15.67%The new financial threat that could wipe out millions… (Ad)During the Internet boom, companies like Pets.com were supposed to be promising investments riding the wave of a new tech boom. But then they were gone within a blink of an eye. One of the most successful investors in history just stepped forward to say the same thing is about to happen to AI stocks.Pay close attention to this important videoMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEYEGAB Corporate Bond ETFN/AN/AN/AN/AN/AN/AN/AN/AMATNMateon TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANVUSNovus TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEYEGAB Corporate Bond ETFN/AN/AN/AN/AMATNMateon TherapeuticsN/AN/AN/AN/ANVUSNovus TherapeuticsN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEYEGAB Corporate Bond ETF$10K2,456.55N/AN/A$1.26 per share27.85MATNMateon TherapeuticsN/AN/AN/AN/A$0.20 per shareN/ANVUSNovus TherapeuticsN/AN/AN/AN/A$13.13 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEYEGAB Corporate Bond ETF-$8.09M-$1.68N/AN/AN/AN/A-104.96%-60.03%N/AMATNMateon Therapeutics-$6.64MN/A0.00N/AN/AN/A-64.66%-42.92%N/ANVUSNovus Therapeutics-$16.01M-$21.58N/AN/AN/AN/A-133.49%-30.52%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEYEGAB Corporate Bond ETFN/AN/AN/AN/AN/AMATNMateon TherapeuticsN/AN/AN/AN/AN/ANVUSNovus TherapeuticsN/AN/AN/AN/AN/ALatest EYEG, NVUS, and MATN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/30/2024EYEGAB Corporate Bond ETFMonthly$0.14845/1/20245/2/20245/7/20243/28/2024EYEGAB Corporate Bond ETFMonthly$0.15724/1/20244/2/20244/5/20242/29/2024EYEGAB Corporate Bond ETFMonthly$0.14863/1/20243/4/20243/7/2024(Data available from 1/1/2013 forward)DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEYEGAB Corporate Bond ETF0.013.073.07MATNMateon TherapeuticsN/A0.170.17NVUSNovus TherapeuticsN/A18.7818.78OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEYEGAB Corporate Bond ETF64.16%MATNMateon Therapeutics0.07%NVUSNovus TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipEYEGAB Corporate Bond ETF58.20%MATNMateon Therapeutics39.22%NVUSNovus Therapeutics2.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableEYEGAB Corporate Bond ETF14700,0005.28 millionNot OptionableMATNMateon Therapeutics1390.24 millionN/ANot OptionableNVUSNovus Therapeutics71.44 millionN/ANot OptionableEYEG, NVUS, and MATN HeadlinesSourceHeadlineCantus Novus Presents: Beauty Surrounds Us In Equality and Peacecentraljersey.com - May 6 at 3:40 PMVivoryon Therapeutics NV VVYmorningstar.com - March 1 at 10:37 PMViking Therapeutics Incmoney.usnews.com - February 22 at 8:11 PMCYT Cyteir Therapeutics, Inc.seekingalpha.com - December 28 at 2:55 PMNovo Holdings invests in US$105 million Series C Funding of Alentis Therapeuticsfinance.yahoo.com - May 11 at 10:47 AMProQR Therapeutics Stock (NASDAQ:PRQR), Analyst Ratings, Price Targets, Predictionsbenzinga.com - March 31 at 6:04 PMSales Revenue from CNS Therapeutics Market to Top US$ 142.1 Billion by 2026: Fact.MR Analysisfinance.yahoo.com - March 30 at 3:52 PMChimeric Therapeutics welcomes “positive” feedback following pre-IND meeting with US FDA for Phase 1 CAR-T studyproactiveinvestors.com - March 29 at 8:06 AMEast Career Technical Academyusnews.com - March 25 at 6:58 PMLas Vegas Academy of the Artsusnews.com - March 25 at 6:58 PMAbout Us – Hartford Courantcourant.com - March 5 at 9:27 AMPerspective Therapeutics Incmoney.usnews.com - February 22 at 3:24 PMOnychomycosis Therapeutics Market Size Worth US$ ~8,420.3 million , Globally, by 2030 at 6% CAGRfinance.yahoo.com - February 12 at 1:14 AMNew MarketBeat Followers Over TimeCompany DescriptionsAB Corporate Bond ETFNASDAQ:EYEGEyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.Mateon TherapeuticsOTCMKTS:MATNMateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.Novus TherapeuticsNASDAQ:NVUSNovus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
